Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Recommendation of “Moderate Buy” by Brokerages

Plus Therapeutics, Inc. (NASDAQ:PSTV) has been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $7.25.

A number of research firms have issued reports on PSTV. Maxim Group cut their price objective on shares of Plus Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Monday, August 18th. Ascendiant Capital Markets dropped their price target on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday, November 21st. Wall Street Zen raised shares of Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 16th. HC Wainwright reiterated a “buy” rating and set a $2.00 price target on shares of Plus Therapeutics in a report on Wednesday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Wednesday, October 8th.

Plus Therapeutics Stock Performance

Shares of PSTV opened at $0.62 on Wednesday. The stock has a 50 day moving average price of $0.60 and a two-hundred day moving average price of $0.48. The firm has a market capitalization of $84.52 million, a P/E ratio of -0.27 and a beta of 0.77. Plus Therapeutics has a 52 week low of $0.16 and a 52 week high of $2.31.

Plus Therapeutics (NASDAQ:PSTV) last announced its earnings results on Thursday, October 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The company had revenue of $1.40 million during the quarter, compared to the consensus estimate of $1.50 million. On average, equities analysts forecast that Plus Therapeutics will post -2.3 earnings per share for the current year.

Institutional Trading of Plus Therapeutics

Several hedge funds have recently added to or reduced their stakes in PSTV. Altium Capital Management LLC bought a new position in shares of Plus Therapeutics during the 3rd quarter valued at approximately $628,000. Scientech Research LLC purchased a new position in Plus Therapeutics in the third quarter valued at approximately $100,000. Jane Street Group LLC bought a new position in Plus Therapeutics during the second quarter valued at $41,000. Susquehanna International Group LLP purchased a new stake in Plus Therapeutics in the third quarter worth $46,000. Finally, Virtu Financial LLC purchased a new stake in Plus Therapeutics in the first quarter worth $38,000. Institutional investors own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.